- Home
- VRE vs CVAC Comparison
VRE vs CVAC Comparison
Compare VRE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRE | CVAC |
|---|---|---|
| Founded | 1949 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRE | CVAC |
|---|---|---|
| Price | $15.05 | $5.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $18.25 | $6.83 |
| AVG Volume (30 Days) | 663.9K | ★ 1.3M |
| Earning Date | 10-22-2025 | 11-24-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | 0.68 | ★ 0.94 |
| Revenue | ★ $291,348,000.00 | $83,000,117.00 |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | N/A | $23.40 |
| P/E Ratio | $23.93 | ★ $5.86 |
| Revenue Growth | ★ 6.39 | N/A |
| 52 Week Low | $13.69 | $2.48 |
| 52 Week High | $18.47 | $5.72 |
Technical Indicators
Market Signals| Indicator | VRE | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 64.99 |
| Support Level | $14.88 | $4.95 |
| Resistance Level | $15.18 | $5.39 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.20 | 94.17 |
Price Performance
Historical ComparisonAbout VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.